

NÖROMUSKULER BLOKÖRLER

7. BÖLÜM

Sedef Gülçin URAL¹

1.Giriş

Asetilkolinin üretimi, salınımı veya reseptörle ilişkisi önlenerek sinir kas iletimi bloke edilir. Kas gevşeticiler asetilkolinin sinir kas kavşağında ilgili reseptöre bağlanmasını önleyerek etki ederler (1-3).

2.Sinir-Kas iletimi ve bloğunu etkileyen faktörler

- Yaş
- Hastalıklar: Sinir ve sinir-kas hastalıkları, Karaciğer hastalıkları, Böbrek yetmezliği, Kollajen doku hastalığı, Elektrolit dengesizliği, Serum proteinleri ve dağılımındaki bozukluklar, obezite
- İlaçlar: Antibiyotikler, İnhalasyon anesteziikleri, Lokal anesteziikleri, Magnezyum
- Diğer etkenler: Vücut ısısı, CO2 düzeyi, Asit-baz dengesizliği, Kas kan akımı (1-17)

3.Depolarizan kas gevşetici ilaçlar

3.1.Faz I (Depolarizan) blok

Grubun tek üyesi olan süksinilkolin (Sch) asetilkolini (Ach) taklit etmesiyle oluşan bloktur. Sch, Ach reseptörlerinin alfa ünitlerine bağlanınca depolarizasyon sonucu iyon kanalları açık kalır ve kas hücreleri yeni uyarılara cevap veremez. Blok gerçekleşmiş olur. Bu bloğun özellikleri;

¹ Uz Dr, Erzurum Şehir Hastanesi, Anesteziyoloji ve Reanimasyon sedef_uzunkaya@hotmail.com

KAYNAKÇA

1. Butterworth FJ, Mackey CD. & Wasnick DJ. (2013). Morgan and Mikhail's Clinical Anesthesiology. (5th ed). New York. McGraw Hill Education.
2. Kayhan Z.,(2019) Klinik Anestezi (4. Baskı).İstanbul:Logos Yayıncılık
3. Sayın M.M. (2012) Kas Gevşeticiler. Yüksel Keçik (Ed.) Keçik Y, Temel Anestezi; pp131-153 Ankara: Güneş Tıp Kitapevleri
4. Lemmens HJ, Brodsky JB. The dose of succinylcholine in morbid obesity. *Anesth Analg* 2006;102:438-442.
5. Lemmens HJ, Brodsky JB. Anesthetic drugs and bariatric surgery. *Expert Rev Neurother* 2006;6:1107-1113.
6. Thapa S, Brull SJ. Succinylcholine-induced hyperkalemia in patients with renal failure: an old question revisited. *Anesth Analg* 2000;91:237-241.
7. Caldwell JE, Heier T, Wright PM, et al. Temperature-dependent pharmacokinetics and pharmacodynamics of vecuronium. *Anesthesiology* 2000;92:84-93.
8. Naguib M, Flood P, McArdle JJ, et al. Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist. *Anesthesiology* 2002;96:202-231.
9. Yamauchi M, Takahashi H, Iwasaki H, et al. Respiratory acidosis prolongs, while alkalosis shortens, the duration and recovery time of vecuronium in humans. *J Clin Anesth* 2002;14:98-101.
10. Müller TC, Rocha JB, Morsch VM, et al. Antidepressants inhibit human acetylcholinesterase and butyrylcholinesterase activity. *Biochim Biophys Acta* 2002;1587:92-98.
11. Zencirci B. Sertraline-induced pseudocholinesterase enzyme deficiency. *Int J Gen Med* 2010;3:375-378.
12. Sahin SH, Colak A, Sezer A, et al. Effect of epidural levobupivacaine on recovery from vecuronium-induced neuromuscular block in patients undergoing lower abdominal surgery. *Anaesth Intensive Care* 2011;39:607-610.
13. Suzuki T, Mizutani H, Ishikawa K, et al. Epidurally administered mepivacaine delays recovery of train-of-four ratio from vecuronium-induced neuromuscular block. *Br J Anaesth* 2007;99:721-725.
14. Munakata K, Suzuki T, Watanabe N, et al.(Influence of epidural lidocaine injection on vecuronium-induced neuromuscular blockade). *Masui* 2004;53:1377-1380.
15. Vivancos GG, Klamt JG, Garcia LV. Effects of 2 mg.kg⁻¹ of intravenous lidocaine on the latency of two different doses of rocuronium and on the hemodynamic response to orotracheal intubation. *Rev Bras Anesthesiol* 2011;61:1-12.
16. Cardoso LS, Martins CR, Tardelli MA. Effects of intravenous lidocaine on the pharmacodynamics of rocuronium. *Rev Bras Anesthesiol* 2005;55:371-380.
17. Czarnetzki C, Lysakowski C, Elia N, et al. Intravenous lidocaine has no impact on rocuronium-induced neuromuscular block. Randomised study. *Acta Anaesthesiol Scand* 2012;56:474-481.
18. Schreiber JU, Lysakowski C, Fuchs-Buder T, et al. Prevention of succinylcholine-induced fasciculation and myalgia: a meta-analysis of randomized trials. *Anesthesiology* 2005;103:877-884.
19. Naguib M, Lien CA, Aker J, et al. Posttetanic potentiation and fade in the response to tetanic and train-of-four stimulation during succinylcholine-induced block. *Anesth Analg* 2004;98:1686-1691.
20. Mace SE. Challenges and advances in intubation: rapid sequence intubation. *Emerg*

- Med Clin North Am 2008;26:1043-1068.
21. Reddy JI, Cooke PJ, van Schalkwyk JM, et al. Anaphylaxis is more common with rocuronium and succinylcholine than with atracurium. *Anesthesiology* 2015;122:39-45.
 22. Tran DT, Newton EK, Mount VA, et al. Rocuronium versus succinylcholine for rapid sequence induction intubation. *Cochrane Database Syst Rev* 2015:CD002788.
 23. Parmentier P, Dagnelie P. Dose-related tachycardia induced by pancuronium during balanced anaesthesia with and without droperidol. *Br J Anaesth* 1979;51:157-160.
 24. Naguib M, Samarkandi AH, Bakhamees HS, et al. Histamine-release haemodynamic changes produced by rocuronium, vecuronium, mivacurium, atracurium and tubocurarine. *Br J Anaesth* 1995;75:588-592.
 25. Chapple DJ, Miller AA, Ward JB, et al. Cardiovascular and neurological effects of laudanosine. Studies in mice and rats, and in conscious and anaesthetized dogs. *Br J Anaesth* 1987;59:218-225.
 26. Szakmany T, Woodhouse T. Use of cisatracurium in critical care: a review of the literature. *Minerva Anesthesiol* 2015;81:450-460.
 27. Dieck T, Steffens J, Sander B, et al. Propofol, remifentanyl and mivacurium: fast track surgery with poor intubating conditions. *Minerva Anesthesiol* 2011;77:585-591.
 28. Maddineni VR, Mirakhur RK, McCoy EP. Recovery of mivacurium block with or without anticholinesterases following administration by continuous infusion. *Anaesthesia* 1994;49:946-948.
 29. Kao YJ, Le ND. The reversal of profound mivacurium-induced neuromuscular blockade. *Can J Anaesth* 1996;43:1128-1133.
 30. Cronnelly R, Morris RB, Miller RD. Edrophonium: duration of action and atropine requirement in humans during halothane anesthesia. *Anesthesiology* 1982; 57:261.
 31. Bevan JC, Collins L, Fowler C, et al. Early and late reversal of rocuronium and vecuronium with neostigmine in adults and children. *Anesth Analg* 1999; 89:333.
 32. Kim KS, Cheong MA, Lee HJ, Lee JM. Tactile assessment for the reversibility of rocuronium-induced neuromuscular blockade during propofol or sevoflurane anesthesia. *Anesth Analg* 2004; 99:1080.
 33. Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of sugammadex. *J Crit Care* 2009; 24:29.
 34. Amorim P, Lagarto F, Gomes B, et al. Neostigmine vs. sugammadex: observational cohort study comparing the quality of recovery using the Postoperative Quality Recovery Scale. *Acta Anaesthesiol Scand* 2014; 58:1101.
 35. Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. *Cochrane Database Syst Rev* 2017; 8:CD012763.
 36. Lee YJ, Oh AY, Koo BW, et al. Postoperative residual neuromuscular blockade after reversal based on a qualitative peripheral nerve stimulator response: A randomised controlled trial. *Eur J Anaesthesiol* 2020; 37:196.
 37. White PF, Tufanogullari B, Sacan O, et al. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex. *Anesth Analg* 2009; 108:846.
 38. Shields M, Giovannelli M, Mirakhur RK, et al. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. *Br J Anaesth* 2006; 96:36.
 39. Sørensen MK, Bretlau C, Gätke MR, et al. Rapid sequence induction and intubation

- with rocuronium-sugammadex compared with succinylcholine: a randomized trial. *Br J Anaesth* 2012; 108:682.
40. Cammu G, De Kam PJ, Demeyer I, et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. *Br J Anaesth* 2008; 100:373.
 41. Gijzenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. *Anesthesiology* 2005; 103:695.
 42. Zwiers A, van den Heuvel M, Smeets J, Rutherford S. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach. *Clin Drug Investig* 2011; 31:101.
 43. Iwasaki H, Sasakawa T, Takahoko K, et al. A case series of re-establishment of neuromuscular block with rocuronium after sugammadex reversal. *J Anesth* 2016; 30:534.
 44. de Kam PJ, Nolte H, Good S, et al. Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy non-anaesthetised volunteers. *Br J Anaesth* 2018; 121:758.
 45. Bhavani SS. Severe bradycardia and asystole after sugammadex. *Br J Anaesth* 2018; 121:95.
 46. Hunter JM, Naguib M. Sugammadex-induced bradycardia and asystole: how great is the risk? *Br J Anaesth* 2018; 121:8.
 47. NDA 2225: Sugammadex Injection. Anesthetic and Analgesic Drug Products Advisory Committee (AC) Meeting November 6, 2015. Available from: <https://www.fda-news.com/ext/resources/files/11-15/110615-merck.pdf?1515434323> (Accessed on July 05, 2018).
 48. Sanoja IA, Toth KS. Profound Bradycardia and Cardiac Arrest After Sugammadex Administration in a Previously Healthy Patient: A Case Report. *A A Pract* 2019; 12:22.